Fig. 3: Antigen retention at vaccination site and delivery to lymph nodes. | Nature Communications

Fig. 3: Antigen retention at vaccination site and delivery to lymph nodes.

From: A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity

Fig. 3

a Scheme of MS@(A647-OVAinMOF) fabrication. b Timeline of the injection of free A647-OVA and MS@(A647-OVAinMOF), and IVIS observation. c Representative images of A647-OVA model cancer antigen residues at the injection sites observed by IVIS fluorescent imaging system for free A647-OVA (upper) and MS@(A647-OVAinMOF) (lower). d Quantitative analysis of A647-OVA fluorescent intensity at the injection site at 6 h, 1 day and 3 day (n = 3 independent animals; Student’s t test, two-tailed). e Scheme of MS@(fOVAinMOF) fabrication. f Timeline of the injection of free fOVA and fOVA-loaded nanoadjuvants and subsequent collection of lymph nodes for cryosection and flow cytometry analysis. g Representative cryosection images of lymph nodes in mice vaccinated with: fOVA, fOVAonMS, MS@(fOVAinMOF) and fOVAinMOF. DAPI, blue; fOVA, green. Scale bars, 50 μm. h Representative flow cytometry plots (left) and populations (right) of CD11c+MHC-I+ dendritic cells with antigen cross-presentation in lymph nodes in mice vaccinated with: fOVA, fOVAonMS, MS@(fOVAinMOF) and fOVAinMOF (n = 3 independent samples, one-way ANOVA followed by Tukey’s multiple comparisons post hoc test, p < 0.0001). All data (d; h, right panel) are presented as mean + S.D.

Back to article page